Gabapentin, originally developed in the 1990s as an anti-seizure medication, has become one of the most widely prescribed drugs for chronic pain conditions, particularly neuropathic pain that affects millions of older adults, including those living with dementia. The drug works by calming overactive nerve signals, and while it was never designed as a painkiller, physicians discovered its effectiveness for conditions like diabetic neuropathy, postherpetic neuralgia (the lingering pain after shingles), and fibromyalgia. For caregivers managing a loved one’s pain alongside cognitive decline, gabapentin has become a familiar name on medication lists — sometimes helpfully, sometimes problematically. The repurposing of gabapentin raises important questions for the brain health community.
Pain management in older adults is already complicated by age-related changes in drug metabolism, polypharmacy risks, and the challenge of assessing pain in someone who may not be able to articulate what they feel. Gabapentin adds another layer: a drug that acts on the central nervous system being given to people whose central nervous system is already compromised. This article examines how gabapentin moved from epilepsy treatment to chronic pain management, what the evidence actually supports, the specific risks for older adults and those with cognitive impairment, and what caregivers and clinicians should weigh before starting or continuing this medication. This is not a simple story of a wonder drug finding a second life. The reality involves aggressive pharmaceutical marketing, off-label prescribing that outpaced the evidence, genuine benefits for certain patients, and real neurological side effects that deserve scrutiny — especially in the context of dementia care and brain health.
Table of Contents
- How Did an Epilepsy Drug Become a Go-To Treatment for Chronic Pain?
- What Does the Evidence Actually Say About Gabapentin for Chronic Pain?
- Gabapentin and the Aging Brain — Risks for Older Adults
- Managing Pain in Dementia Patients — Where Gabapentin Fits and Where It Doesn’t
- Dependence, Withdrawal, and the Challenge of Deprescribing Gabapentin
- The Regulatory Landscape and Growing Scrutiny
- What Comes Next — Alternatives and Evolving Approaches to Neuropathic Pain
- Conclusion
- Frequently Asked Questions
How Did an Epilepsy Drug Become a Go-To Treatment for Chronic Pain?
Gabapentin was approved by the FDA in 1993 under the brand name Neurontin, initially as an add-on therapy for partial seizures in epilepsy. Its mechanism involves binding to a specific subunit of voltage-gated calcium channels in the nervous system, which reduces the release of excitatory neurotransmitters. Researchers noticed early on that patients taking gabapentin for seizures reported improvements in pain symptoms, which prompted clinical trials for pain conditions. By 2002, the FDA had approved gabapentin for postherpetic neuralgia — the burning, stabbing pain that can persist for months or years after a shingles outbreak. That approval opened the floodgates for off-label prescribing across a wide range of pain conditions. The expansion was not entirely organic.
Pfizer’s subsidiary Warner-Lambert paid over $430 million in 2004 to settle federal charges that it had illegally promoted Neurontin for unapproved uses, including pain conditions, migraines, and bipolar disorder. Internal documents revealed a systematic campaign to encourage doctors to prescribe the drug for conditions where evidence was thin or nonexistent. Despite this, the off-label use stuck. By the time generic gabapentin became widely available, it had embedded itself in pain management protocols across primary care, neurology, and geriatric medicine. As of recent reports, gabapentin has consistently ranked among the most prescribed medications in the United States, with hundreds of millions of prescriptions filled annually. A related drug, pregabalin (marketed as Lyrica), works through a similar mechanism and received FDA approval for fibromyalgia, diabetic neuropathy, and postherpetic neuralgia. Pregabalin is often compared to gabapentin, though it tends to be more potent, more expensive, and has been classified as a Schedule V controlled substance due to its potential for misuse — a classification gabapentin has avoided at the federal level, though several states have added their own restrictions.
What Does the Evidence Actually Say About Gabapentin for Chronic Pain?
The evidence supporting gabapentin for chronic pain is more mixed than its prescribing patterns would suggest. For postherpetic neuralgia and diabetic peripheral neuropathy, clinical trials have shown moderate benefit — typically a reduction in pain scores of around 30 percent in roughly 30 to 40 percent of patients, according to systematic reviews published in the Cochrane Database. That means the majority of patients in these trials did not experience meaningful relief. The drug performs better than placebo, but the gap is not as dramatic as many assume, and the “number needed to treat” — how many patients must take the drug for one to benefit — has historically hovered in a range that some researchers consider modest. For other chronic pain conditions, the picture grows murkier.
Gabapentin is frequently prescribed for low back pain, cancer-related pain, and general chronic pain syndromes, but high-quality evidence supporting these uses is limited. A notable study published in The Lancet in 2017 found that pregabalin (gabapentin’s close relative) was no more effective than placebo for sciatica-related leg pain, challenging assumptions about the entire drug class for radicular pain. Reviews of gabapentin for chronic low back pain have similarly found insufficient evidence of benefit. However, if a patient’s pain has a clear neuropathic component — nerve damage, burning sensations, electric-shock-type pain — the drug is more likely to provide some relief than for purely musculoskeletal or inflammatory pain. One important limitation is that most clinical trials studying gabapentin enrolled relatively young, healthy participants and excluded older adults with multiple comorbidities or cognitive impairment. this means the evidence base may not accurately reflect how the drug performs in the very populations most likely to receive it: elderly patients with complex medical histories.
Gabapentin and the Aging Brain — Risks for Older Adults
The central nervous system effects of gabapentin deserve particular attention in older adults. Common side effects include dizziness, drowsiness, fatigue, and problems with coordination — symptoms that in an elderly person can directly increase fall risk. Falls are a leading cause of serious injury and death in older adults, and any medication that impairs balance and alertness compounds that danger. Studies have linked gabapentinoid use in older populations to increased rates of falls and hip fractures, with some research suggesting the risk is highest in the first weeks after starting the medication or increasing the dose. Cognitive side effects are especially concerning for the brain health community. Gabapentin can cause confusion, difficulty concentrating, and memory problems even in younger patients.
In someone already experiencing mild cognitive impairment or early-stage dementia, these effects can be difficult to distinguish from disease progression. A caregiver might notice increased confusion or drowsiness in a loved one with Alzheimer’s disease and attribute it to worsening dementia, when in reality the gabapentin is contributing to or causing the change. This diagnostic masking is a real and underappreciated problem in geriatric care. There is also emerging research exploring whether gabapentinoids might have longer-term effects on cognitive function. While gabapentin is not classified as an anticholinergic drug — a class known to increase dementia risk — its impact on the central nervous system warrants caution in populations vulnerable to cognitive decline. Clinicians specializing in geriatric pharmacology generally recommend starting at lower doses and titrating slowly in older patients, but in practice, dosing adjustments do not always happen. A patient may be started on gabapentin at 65 and still be taking the same dose at 82, with no reassessment of whether the benefit still outweighs the risk.
Managing Pain in Dementia Patients — Where Gabapentin Fits and Where It Doesn’t
Pain management in dementia care is one of the most difficult challenges families and clinicians face. People with moderate to advanced dementia may not be able to verbalize pain, leading to undertreatment. They may instead express pain through agitation, aggression, withdrawal, or changes in appetite and sleep. Behavioral tools like the PAINAD (Pain Assessment in Advanced Dementia) scale exist to help identify pain, but they require trained observers and are not universally used. In this context, gabapentin sometimes enters the picture as a relatively safe-seeming option — it is not an opioid, it is not a benzodiazepine, and it is perceived as carrying fewer risks than many alternatives. The tradeoff is real but not straightforward.
Compared to opioids, gabapentin does not carry the same risk of respiratory depression or the same degree of physiological dependence, though withdrawal effects (including seizures) can occur if it is stopped abruptly. Compared to nonsteroidal anti-inflammatory drugs like ibuprofen, gabapentin avoids gastrointestinal bleeding risk and kidney strain — both significant concerns in older adults. However, gabapentin’s cognitive and sedative effects may be more problematic in a dementia patient than the carefully monitored, short-term use of other analgesics. There is no universally correct answer; the choice depends on the type of pain, the individual’s overall health, their cognitive status, and what other medications they are taking. For neuropathic pain specifically — such as the persistent burning a dementia patient might experience from diabetic neuropathy or post-shingles neuralgia — gabapentin may be a reasonable option when started at a low dose with careful monitoring. For general aches, arthritis pain, or discomfort without a clear nerve component, there is little evidence that gabapentin will help, and the side effect burden may not be justified.
Dependence, Withdrawal, and the Challenge of Deprescribing Gabapentin
One aspect of gabapentin that has received increasing attention is the difficulty of stopping it once started. Although gabapentin is not considered addictive in the traditional sense, physical dependence develops with regular use. Abrupt discontinuation can trigger withdrawal symptoms including anxiety, insomnia, nausea, sweating, and in some cases, seizures — even in patients who have never had a seizure disorder. This means that gabapentin cannot simply be stopped; it must be tapered gradually, sometimes over weeks or months. Deprescribing — the intentional, supervised process of reducing or stopping medications that may no longer be beneficial — is a growing area of focus in geriatric medicine.
Gabapentin is frequently flagged as a candidate for deprescribing in older adults, particularly when the original indication is unclear, the pain condition has changed, or cognitive side effects have become apparent. However, the tapering process itself can be uncomfortable, and some patients or caregivers resist changes to a medication regimen that feels stable. For a person with dementia, the behavioral changes associated with gabapentin withdrawal could be misinterpreted as worsening of the disease or as behavioral disturbance, complicating the process further. Clinicians experienced in geriatric deprescribing recommend slow tapers with close monitoring, clear communication with caregivers about what to expect, and a plan for alternative pain management strategies. If a patient has been on gabapentin for years without a recent reassessment of whether the pain still exists or responds to the medication, a thoughtful trial reduction may reveal that the drug is no longer needed.
The Regulatory Landscape and Growing Scrutiny
Several U.S. states have reclassified gabapentin as a controlled substance, responding to reports of misuse, diversion, and its appearance in combination with opioids in overdose deaths. While the federal government has not followed suit as of recent reports, the trend signals growing awareness that gabapentin is not the harmless, all-purpose medication it was once perceived to be.
The United Kingdom reclassified gabapentin and pregabalin as Class C controlled substances in 2019, citing concerns about misuse and a pattern of the drugs being found in the systems of people who died from drug overdoses. For the dementia care community, the controlled-substance debate is less about misuse potential and more about what the scrutiny reveals: that gabapentin’s risks have been systematically underestimated. When a drug is easy to prescribe, perceived as safe, and effective for a broad symptom like pain, it tends to accumulate on medication lists without regular review. The growing regulatory attention may ultimately benefit older adults by prompting more frequent reassessment of whether gabapentin remains appropriate.
What Comes Next — Alternatives and Evolving Approaches to Neuropathic Pain
Research into neuropathic pain continues to evolve, with several directions that could eventually reduce reliance on gabapentinoids. Targeted therapies aimed at specific sodium channel subtypes, topical treatments like high-concentration capsaicin patches, and neuromodulation techniques such as transcutaneous electrical nerve stimulation are all areas of active investigation. For older adults with cognitive impairment, non-pharmacological approaches — including physical therapy, gentle movement, warm compresses, massage, and environmental modifications to reduce discomfort — deserve more emphasis than they typically receive in clinical practice.
The broader shift toward personalized, multimodal pain management is encouraging, even if progress is slow. For families navigating pain in a loved one with dementia, the most practical step remains advocating for regular medication reviews, asking specifically whether each drug on the list is still serving a purpose, and ensuring that pain assessment — not just pain medication — is part of every clinical visit. Gabapentin will likely remain a useful tool for the right patient and the right type of pain. The goal is making sure it is used deliberately, not by default.
Conclusion
Gabapentin’s journey from anti-seizure medication to chronic pain staple reflects both the promise and the pitfalls of drug repurposing. For certain neuropathic pain conditions, it provides genuine relief that can meaningfully improve quality of life. But its widespread off-label use, particularly in older adults and people with cognitive impairment, has outpaced the evidence and introduced risks — cognitive dulling, increased fall danger, diagnostic masking, and difficult withdrawal — that are too often overlooked.
For caregivers and families in the dementia care space, the takeaway is not that gabapentin should be feared or avoided categorically. Rather, it should be questioned actively. Is the pain neuropathic? Has the benefit been reassessed recently? Are there cognitive or balance changes that might be medication-related rather than disease-related? Could a lower dose or a different approach work? These are the conversations worth having with a prescribing clinician, and they are conversations that can make a real difference in a person’s comfort and clarity of mind.
Frequently Asked Questions
Is gabapentin safe for someone with Alzheimer’s disease or dementia?
There is no absolute contraindication, but gabapentin carries heightened risks in people with cognitive impairment. Side effects like confusion, drowsiness, and memory problems can worsen existing cognitive symptoms or be mistaken for disease progression. If gabapentin is used, it should be started at a low dose, monitored closely, and reassessed regularly.
Can gabapentin cause or worsen dementia?
Gabapentin is not currently classified as a medication that causes dementia. However, it can produce reversible cognitive side effects — brain fog, confusion, impaired concentration — that may mimic or exacerbate dementia symptoms. These effects are generally dose-dependent and resolve when the drug is reduced or discontinued, though this has not been studied extensively in long-term users.
What are the alternatives to gabapentin for nerve pain in older adults?
Depending on the type and location of pain, alternatives may include topical lidocaine patches, duloxetine (an antidepressant with evidence for neuropathic pain), low-dose tricyclic antidepressants (used cautiously due to anticholinergic effects), capsaicin cream, and non-pharmacological approaches such as physical therapy or transcutaneous electrical nerve stimulation. Each has its own risk profile, and the best choice depends on the individual patient.
How long does it take to taper off gabapentin?
Tapering schedules vary depending on the dose and how long the person has been taking the drug. A general guideline is to reduce the dose by no more than 10 to 25 percent every one to two weeks, but some patients require even slower reductions. The process can take several weeks to a few months. It should always be done under medical supervision.
Why is my loved one’s doctor prescribing gabapentin if the evidence is mixed?
Chronic pain management in older adults involves difficult tradeoffs. Many alternatives carry their own significant risks — opioids can cause sedation and respiratory depression, NSAIDs can damage kidneys and cause bleeding, and undertreated pain has its own serious health consequences. Gabapentin occupies a middle ground that many clinicians find pragmatically useful, even when the evidence is imperfect. The key is ensuring the prescribing decision is revisited periodically.
